WALTHAM, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- FluidForm Bio™, a leader in cell therapies for chronic diseases such as type 1 diabetes, today announced that Mike Graffeo, CEO and co-founder, will delivery a company overview and conduct one-on-one meetings at the New England Venture Summit, which is being held December 10-11 in Boston, MA.
Details of the presentation are as follows:
Date: Wednesday, December 11, 2024
Time: 10:00am ET
In addition to a corporate update, FluidForm will share data on its lead program in islet cell replacement therapy. A critical factor for the success of islet cell replacement therapy is the promotion of vascularization to support rapid engraftment and promote long-term cell viability. The data demonstrate that this approach drives rapid vascularization throughout the tissue, ensuring that islets receive adequate blood supply, which is essential for long-term cell survival and function. By reducing early islet loss, the therapy will be more durable, eliminating the need for supplemental infusions that are often required with other methods. This durability is expected to translate into a more stable and long-term treatment for patients, reducing the frequency of medical interventions and improving the quality of life.
Registrants can request one-on-one meetings with FluidForm management, and more information about the Summit can be found at the following link: https://youngstartup.com/events/nevs24/
About FluidForm Bio™
FluidForm Bio™ is a biotechnology company developing next-generation cell therapies for chronic diseases leveraging its proprietary FRESH™ 3D bioprinting technology platform. Using FRESH, FluidForm creates functional tissue with the same materials found in the human body, eliminating chemistries and materials known to trigger negative immune response. FRESH is a powerful vascularization platform, allowing the building of densely cellular vascularized tissue that maintains viability upon implant.
The company’s lead program is an islet cell therapy for type 1 diabetes in which insulin-producing beta cells are arranged in a tissue scaffold ready for subcutaneous implantation. This method is less invasive and less toxic when compared to other delivery sites, offering retrievability and reducing surgical risks and recovery time for patients.
This novel approach to islet cell replacement therapy presents a transformative advancement in diabetes treatment. With superior fabrication techniques, enhanced vascularization, a robust immune modulation platform, and a convenient subcutaneous implant, this method addresses many limitations of current technologies. These improvements offer the potential for a more effective, durable, and patient-friendly therapy, offering new hope for individuals with diabetes.
Founded in 2018, FluidForm is headquartered in Waltham, MA. To learn more, please visit: fluidformbio.com or connect on Twitter and LinkedIn.
Contact:
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
